Synthesis and Pharmacological Evaluation of New Progesterone Esters as 5α-Reductase Inhibitors
-
- Ramírez Elena
- Department of Pharmacy, Faculty of Chemistry, National University of Mexico City, Mexico D.F.
-
- Cabeza Marisa
- Departments of Biological Systems and Animal Production, Metropolitan University-Xochimilco
-
- Bratoeff Eugene
- Department of Pharmacy, Faculty of Chemistry, National University of Mexico City, Mexico D.F.
-
- Heuze Ivonne
- Departments of Biological Systems and Animal Production, Metropolitan University-Xochimilco
-
- Pérez Víctor
- Department of Pharmacy, Faculty of Chemistry, National University of Mexico City, Mexico D.F.
-
- Valdez David
- Department of Pharmacy, Faculty of Chemistry, National University of Mexico City, Mexico D.F.
-
- Ochoa Martha
- Department of Pharmacy, Faculty of Chemistry, National University of Mexico City, Mexico D.F.
-
- Teran Nayeli
- Department of Pharmacy, Faculty of Chemistry, National University of Mexico City, Mexico D.F.
-
- Jimenez Geidy
- Department of Pharmacy, Faculty of Chemistry, National University of Mexico City, Mexico D.F.
-
- Ramírez Teresa
- Institute of Chemistry, National University of Mexico City, Mexico D.F.
書誌事項
- タイトル別名
-
- Synthesis and Pharmacological Evaluation of New Progesterone Esters as 5.ALPHA.-Reductase Inhibitors
- Synthesis and Pharmacological Evaluation of New Progesterone Esters as 5 アルファ Reductase Inhibitors
この論文をさがす
抄録
In this study we report the synthesis and pharmacological evaluation of four new progesterone derivatives; 17α-hydroxy-16β-methylpregna-4,6-diene-3,20-dione 12, 17α-cyclopropylcarbonyloxy-16β-methylpregna-4,6-diene-3,20-dione 13, 17α-cyclobutylcarbonyloxy-16β-methylpregna-4,6-diene-3,20-dione 14, 17α-acetoxy-16β-methylpregna-4,6-diene-3,20-dione 15 and the pregnatriene compound 17α-cyclobutylcarbonyloxy-16β-methylpregna-1,4,6-triene-3,20-dione 16. The pharmacological effect of these compounds was determined in vivo as well as in vitro. The evaluation in vivo was carried out on gonadectomized male hamsters that were injected subcutaneously daily with testosterone (T) and/or finasteride, or with the novel compounds. At the end of the treatments the animals were sacrificed and the prostates were weighed. It was observed that when testosterone (T) and finasteride or compounds 12—16 were injected together, the weight of the prostate decreased significantly as compared to that of the testosterone-treated animals. The 5α-reductase inhibitory activity was evaluated in vitro using human prostate homogenates. These experiments showed the following IC50 values: compound 12 (alcohol at C-17) 1.2×10−6 M, 13 (cyclopropyl substituent at C-17) 7.9×10−10 M, 14 (cyclobutyl substituent) 3.2×10−8 M, 15 (acetoxy substituent) 6.3×10−11 M and 16 (cyclobutyl substituent) 3.9×10−6 M. It is evident from these data that when the size of the substituent at C-17 is decreased, the 5α-reductase inhibitory activity increases. Apparently, in this biological model, the 5α-reductase inhibitory activity depends upon the steric effect of the substituent at C-17. However, the free alcohol 12 showed much lower 5α-reductase inhibitory activity.
収録刊行物
-
- CHEMICAL & PHARMACEUTICAL BULLETIN
-
CHEMICAL & PHARMACEUTICAL BULLETIN 53 (12), 1515-1518, 2005
公益社団法人 日本薬学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390282679145303680
-
- NII論文ID
- 110004049467
-
- NII書誌ID
- AA00602100
-
- ISSN
- 13475223
- 00092363
-
- NDL書誌ID
- 7720628
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- NDL
- Crossref
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可